Advertisement

Topics

Oral Drug to Treat Uterine Fibroids Boasts Phase III Success

05:31 EDT 4 Oct 2017 | Labiotech.eu

Myovant’s partner Takeda has reported Phase III results showing relugolix to be more effective in treating uterine fibroids than existing hormonal therapy.  Myovant has announced positive results from its lead candidate, relugolix, which showed itself to be better than leuprorelin injections — ...

This awesome article Oral Drug to Treat Uterine Fibroids Boasts Phase III Success appeared first on Labiotech.eu. Be kind and don't copy it without asking ;)

Original Article: Oral Drug to Treat Uterine Fibroids Boasts Phase III Success

NEXT ARTICLE

More From BioPortfolio on "Oral Drug to Treat Uterine Fibroids Boasts Phase III Success"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...